A 13-year Survey of Pneumococcal Nasopharyngeal Carriage in Children with Acute Otitis Media Following PCV7 and PCV13 Implementation
Overview
Authors
Affiliations
Background: This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae serotypes in children with acute otitis media and modified the resistance of this bacterial species to antibiotics.
Methods: Between 2001 and 2014, 121 pediatricians obtained nasopharyngeal swabs from children with acute otitis media aged 6-24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci. Demographics, medical history and physical examination findings were recorded.
Results: Over the 13 years, among the 7991 enrolled patients, the proportion of PCV-vaccinated children (≥1 dose) increased (54.3-99.7%, p<0.001). Overall, pneumococcal carriage was reduced from 71.2% to 56.2% from 2001 to 2014 (p<0.001) and carriage of PCV7 serotypes (STs) from 44.5% to 1.2% (p<0.001). The carriage of 6 additional STs plus 6C increased from 17.2% to 24.3% from 2001 to 2010 (p<0.001) and decreased after PCV13 implementation (21.4-3.5%, p<0.001). The proportion of ST 19A carriage increased from 8.6% to 15.8% from 2001 to 2010 (p<0.001) and decreased to 1.2% in 2014. After PCV13 implementation, the most frequently carried non-PCV13 STs were ST 15B/C, 11A, 15A, and 35B. Penicillin non-susceptible pneumococcal strains decreased from 67.1% in 2001 to 33.1% in 2014 (p<0.001).
Conclusions: By the number of patients enrolled and the duration, this study is the largest performed to date. It allows to demonstrate a strong impact of PCVs and to describe the complex dynamics of pneumococcal carriage during AOM. As pneumococcal carriage decreased during AOM, a reduction in the incidence of pneumococcal AOM could be expected.
Ricci Conesa H, Skroder H, Norton N, Bencina G, Tsoumani E PLoS One. 2024; 19(4):e0297098.
PMID: 38564583 PMC: 10986968. DOI: 10.1371/journal.pone.0297098.
Yokota S, Tsukamoto N, Sato T, Ohkoshi Y, Yamamoto S, Ogasawara N IJID Reg. 2023; 8:105-110.
PMID: 37554357 PMC: 10404989. DOI: 10.1016/j.ijregi.2023.07.002.
Rybak A, Levy C, Ouldali N, Bonacorsi S, Bechet S, Delobbe J Antibiotics (Basel). 2023; 12(6).
PMID: 37370339 PMC: 10295685. DOI: 10.3390/antibiotics12061020.
Discovery and Characterization of Pneumococcal Serogroup 36 Capsule Subtypes, Serotypes 36A and 36B.
Ganaie F, Saad J, Lo S, McGee L, Bentley S, van Tonder A J Clin Microbiol. 2023; 61(4):e0002423.
PMID: 36971549 PMC: 10117043. DOI: 10.1128/jcm.00024-23.
Shinohara K, Fujisawa T, Chang B, Ito Y, Suga S, Matsumura Y Antimicrob Agents Chemother. 2023; 67(2):e0108322.
PMID: 36651739 PMC: 9933736. DOI: 10.1128/aac.01083-22.